Objective To investigate whether there are changes in the ability of intertemporal choices in migraine sufferers. Method Thirty migraine sufferers and thirty healthy controls were investigated by Delay?discount Test. Results (1)The ratio of later?large (LL) choice in migraine suffers((18.15± 17.53)%) was significantly lower than that in the healthy controls((35.37±20.70)%),and the difference was statistically significant(t=3.31, P<0.05).Under the immediate option for now selection conditions and no immediate option for not?now selection conditions,the ratio of later?large (LL) choice in migraine suffers ((18.33±21.00)% ,(17.96±18.09)%) was also significantly lower than that in the healthy controls ((35.56±21.52)%,(35.19±22.05)%),and the difference was statistically significant(t=3.31, P<0.05;t=3.14, P<0.05).(2) Pearson correlation analysis showed that the Stroop Test of migraineurs was positively correlated with LL selection ratio under now conditions (r=0.49, P=0.006) and total LL selection (r=0.42, P=0.021) . Conclusion The ability of intertemporal choices in migraine sufferers has been impaired,which is correlated with executive function.

Objective To explore the characteristics of emotional memory in adolescent with anxiety disorders.Methods Totally 40 adolescent patients with anxiety disorders who met the DSM-5 diagnostic criteria were selected as the anxiety disorder group,40 normal adolescents matched with anxiety disorder group in terms of gender,age and education level served as the control group.All subjects of the two groups were implemented by emotional memory test task.Results (1) In emotional memory test,the negative picture score of adolescent anxiety disorder group(2.10±0.75)was significantly lower than that of control group (2.76±0.92) (t=-3.29,P＜0.05).There were no significant difference in positive and neutral picture scores between the two groups(P＞0.05).(2)Compared with control group,the positive picture,neutral picture and total recognition accuracy of adolescent anxiety disorder group both were significantly decreased ((0.24±0.09) vs (0.33±0.08),(0.22±0.10) vs (0.32±0.14),(0.25±0.08) vs (0.33±0.09)) (t=-4.28,-4.28,-3.85,all P＜0.05).There was no significant difference in negative picture recognition accuracy between the two groups (P＞0.05).In adolescent anxiety disorder group,there were significant differences in the correct recognition rates of negative pictures,positive pictures and neutral pictures in anxiety disorder group (F=3.39,P＜0.05),while there was no significant difference in the control group (F=0.04,P＞0.05).(3) The positive picture recognition accuracy and total recognition accuracy in adolescent anxiety disorder group were negatively correlated with Hamilton Anxiety Scale (HAMA) (F=0.04,P＜ 0.05).Conclusion Adolescent anxiety disorders exist in emotional memory defects,and its positive emotional memory deficit is negatively correlated with the severity of anxiety.

Objective To explore whether the ability of intertemporal choice is impaired in schizophrenic patients and in their unaffected siblings.Methods Twenty-five schizophrenia patients,twenty-five unaffected siblings of patients and thirty healthy controls were recruited in the study."Delay-discounting" task and a battery of cognitive neuropsychological assessment were used to examine the intertemporal decision-making.Results (1) the value of k was ((0.005±0.009 in schizophrenia,0.011±0.014 in unaffected siblings and 0.024±0.029 in healthy controls,respectively.There was significant difference in k value among these three groups (F=9.487,P＜0.001).There were significant differences in k value between patients group and healthy controls,and between unaffected siblings and healthy controls (P＜0.05).There was no significant difference between schizophrenia and their unaffected siblings (P＜0.05).(2) Pearson correlation analysis not showed any relationship between neuropsychological test and the value of k.Conclusion The ability of intertemporal choices is impaired in schizophrenia and their unaffected siblings to a great degree.

Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Humans ; Lymphoma, Follicular ; drug therapy ; Rituximab

OBJECTIVEA prospective, multicenter and non-interventional prospective study was conducted to evaluate the clinical features of rituximab combined with chemotherapy (R-Chemo) as first-line treatment on newly diagnosed Chinese patients with diffuse large B-cell lymphoma (DLBCL).

METHODSThis was a single arm, prospective, observational multicenter and phase IV clinical trial for 279 patients, who were newly diagnosed as CD20-positive DLBCL from 24 medical centers in China 2011 and 2012, no special exclusion criteria were used. All patients received rituximab based R-Chemo regimes, such as R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone) and other regimes as the first-line treatment. The treatment strategies were determined by physicians and patients without detailed description for treatment course, dose, interval time and examination. Clinical response and safety of all patients were investigated in 120 days after completion of last dose of rituximab.

RESULTSOf 279 patients, 258 with stage I-IV who received at least 1 cycle of rituximab treatment and completed at least one time of tumor assessment were enrolled into intention-to-treat analysis, including 148 male and 110 female. The median age of all patients was 57.2(12.8-88.4) years. ECOG performance statuses of 0 or 1 were observed in 91.1% of patients, international prognostic index levels in the low-risk and low-middle-risk groups in 76.4% of patients, the tumor diameters smaller than 7.5 cm in 69.0% of patients. All patients received 6 median cycles of R-Chemo treatment every 24.4 days. R-CHOP treatment was shown to improve the clinical response with overall response rates of 94.2%. Common adverse events included anemia, marrow failure, leukopenia, thrombocytopenia, digestive diseases, infection and liver toxicity. All adverse events are manageable.

CONCLUSIONNon-interventional clinical trial of R-Chemo remains the standard first-line treatment for newly diagnosed patients with DLBCL in real clinical practice, which is consistent with international treatment recommendations for DLBCL patients. R-Chemo can provide the clinical evidence and benefit as the first-line standard treatment for Chinese patients with DLBCL.

Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Child ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; Male ; Middle Aged ; Prospective Studies ; Rituximab ; Treatment Outcome